120 results found

Brazil is the eighth largest pharmaceutical market in terms of revenue and Latin America's largest markets.

A lei 15.471/26 instituiu a Estratégia Nacional de Saúde do Complexo Econômico-Industrial da Saúde (ENSCEIS), conferindo status legal a políticas anteriormente baseadas apenas em atos infralegais. Embora represente avanços ao consolidar programas como as Parcerias para o Desenvolvimento Produtivo (PDPs), a nova legislação apresenta falhas de clareza, insegurança jurídica em disposições importantes e riscos de criar reservas de mercado que podem pos

O julgamento que envolve a retroatividade/irretroatividade das alterações trazidas pela Lei nº 14.320/2021, na Lei de Improbidade Administrativa, recebeu um novo capítulo no dia 22/04/2022.

Confira a nossa análise dos principais temas para 2026–2027 e seus impactos em Life Sciences, Saúde, Alimentos, Cosméticos e Dispositivos Médicos

A má compreensão do papel de aplicativos como BlaBlaCar, iFood e Airbnb pode dar ensejo a decisões que geram insegurança jurídica...

Confira os principais movimentos regulatórios que impactam setores como saúde suplementar, farmacêutico, cosméticos, alimentos, biotecnologia e produtos sujeitos à regulação do MAPA...

A publicação Análise Editorial divulgou em março o seu novo ranking "Análise Advocacia Mulher".

Explore the key regulatory updates from May 2026 affecting Brazil's healthcare and pharmaceutical sectors, including new rules for clinical research, drug pricing mechanisms, supplemental health insurance adjustments...

Check recent decisions by regulatory agencies such as Anvisa and ANTT, as well as bills passed by Congress, that affect strategies and operations in regulated sectors...

A recent decision by Brazil's Federal Regional Court of the 1st Region confirms that the Ministry of Agriculture holds final authority over agrochemical use decisions following environmental assessments by Ibama. This ruling addresses regulatory inconsistencies in the re-evaluation process of active ingredients, particularly regarding imidacloprid, and establishes that uniform treatment must apply to both registered products and new registration requests.

Confira recentes decisões de agências reguladoras como Anvisa e ANTT, além de projetos de lei aprovados no Congresso, que influenciam estratégias e operações em setores sujeitos à regulação...

New regulations and technical adjustments expand compliance requirements, tighten safety criteria, and seek greater efficiency in regulatory processes and market access across Brazil's life sciences sector. This newsletter compiles the most critical regulatory updates affecting pharmaceuticals, supplementary health, food products, and other regulated sectors under ANVISA and professional councils.

To date, 2024 has not yet seen the type of mega-merger (Pfizer/Seagen) or level of agency enforcement (Sanofi/Maze or Amgen/Horizon) as 2023. But two notable investigations — one still active — show...

This page appears to be a security verification checkpoint that temporarily blocks access while validating the incoming request. The system implements protective measures to distinguish legitimate users from automated traffic or potential security threats.

Regulatory updates from ANVISA, CFM, and CFF shape strategic decisions across pharmaceutical, medical device, and supplementary health sectors. This edition covers key regulatory movements affecting strategic sectors including pharmaceutical industry, supplementary health, food products, and other regulated products, including cases involving regulatory interface with ANVISA and professional councils.

Explore as principais mudanças regulatórias que impactam indústria farmacêutica, saúde suplementar, alimentos e produtos regulados pela Anvisa. Descubra como novas resoluções sobre gases medicinais, saneantes, dispositivos médicos e teleatendimento em saúde mental afetam estratégias de negócio e conformidade regulatória no Brasil.

Explore the latest regulatory updates impacting Brazil's pharmaceutical, healthcare, cosmetics, and medical device industries in June. From ANVISA's new pharmacovigilance system to CFM's platform against medical practice violations, discover how these changes create both compliance challenges and strategic opportunities for industry stakeholders.

Brazil's life sciences regulatory framework combines centralized federal oversight through ANVISA with a comprehensive legal structure governing medicinal products, biologicals, medical devices...